Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.

S Kumar,E. Ma,A. Engebretson,Francis Buadi,Martha Q. Lacy,Angela Dispenzieri,Mei Sheng Duh,Marie-Hélène Lafeuille,Patrick Lefebvre,Wendy Y. Cheng,Katherine Dea,Debra Rembert,Debra Patt,Liviu Niculescu,M. Quick,S V Rajkumar

Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.

2016

S Kumar
E. Ma
A. Engebretson
Francis Buadi
Martha Q. Lacy
Angela Dispenzieri
Mei Sheng Duh
Marie-Hélène Lafeuille
Patrick Lefebvre
Wendy Y. Cheng
Katherine Dea
Debra Rembert
Debra Patt
Liviu Niculescu
M. Quick
S V Rajkumar

Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma

Keywords:

Dexamethasone
Cancer research
Hematology
Thalidomide
Bortezomib
Lenalidomide
Leukemia
Multiple myeloma
Internal medicine
Medicine
Cyclophosphamide
Oncology
Survival rate
Surgery

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations